AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01035021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of rocuronium when the LMA is inserted
Description: Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
Study NCT04592666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: the standard therapy of single agent almonertinib
Study NCT04592666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: the standard therapy of single agent almonertinib
Study NCT04592666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard dose
Study NCT04592666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5
Study NCT02116374 — intervention group
Intervention type: OTHER
Intervention: Physiopathology study
Study NCT03225950 — intervention group
Intervention type: OTHER
Intervention: In vitro stimulation of blood with periodontitis-associated- and control bacteria
Description: Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
Study NCT03225950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-CCP- and anti-P.g.-antibodies titers
Description: Anitbody titers will be measured in saliva and serum samples.
Study NCT03225950 — intervention group
Intervention type: GENETIC
Intervention: Analysis of selected single nucleotide polymorphisms (SNPs)
Description: DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
Study NCT03225950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: periodontitis-associated bacteria presence
Description: Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
Study NCT02763410 — intervention group
Intervention type: OTHER
Intervention: PRBC transfusion
Study NCT04510870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
Study NCT04510870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl infusion
Description: Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
Study NCT00734318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 250/10 micrograms
Study NCT00734318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform 50/5 micrograms
Study NCT00734318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms
Study NCT00734318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide pMDI 250 micrograms
Study NCT00519909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dairy calcium
Description: Diets with different content of calcium and fat
Study NCT04344886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional (dual-phase) SPECT/CT
Description: Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
Study NCT04344886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-phase SPECT/CT
Description: Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
Study NCT04344886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional minimally-invasive radio-guided parathyroidectomy
Description: Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
Study NCT04344886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualised minimally-invasive radio-guided parathyroidectomy
Description: Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
Study NCT02861716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.
Study NCT02861716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.
Study NCT02861716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study NCT00838175 — intervention group
Intervention type: PROCEDURE
Intervention: suture mediated closure
Description: Suture mediated closure of femoral venous access
Study NCT01994369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study NCT03621566 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Routine care (registry)
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear study
Study NCT02284477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non- PVC containing packing materials
Description: Beverage which was stored in glass bottle for 24 hours in 4 ℃.
Study NCT02284477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVC containing packing materials
Description: Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
Study NCT04725435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
Study NCT04725435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking Position
Description: Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure.
Study NCT03569670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior stabilized all-polyethylene tibial component
Description: Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
Study NCT03569670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate retaining all-polyethylene tibial component
Description: Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
Study NCT00866632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
Study NCT00866632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
Study NCT01248299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FU-CDDP
Description: every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]
Study NCT01248299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP
Description: every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]
Study NCT01248299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]
Study NCT01248299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF
Description: every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]
Study NCT01248299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 50 ug
Description: Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 200 ug
Description: Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 500 ug
Description: Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly I:Poly C12U 1250 ug
Description: Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo; 3 doses; nasal administration every 28 days
Study NCT01591473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5μg/kg SHR0410
Description: a single dose of 0.5μg/kg SHR0410
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1μg/kg SHR0410
Description: a single dose of 2μg/kg SHR0410
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2μg/kg SHR0410
Description: a single dose of 2μg/kg SHR0410
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5μg/kg SHR0410
Description: a single dose of 5μg/kg SHR0410
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10μg/kg SHR0410
Description: a single dose of 10μg/kg SHR0410
Study NCT03493191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20μg/kg SHR0410
Description: a single dose of 20μg/kg SHR0410
Study NCT00318890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
Study NCT03254134 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: patients treated with warfarin
Study NCT03254134 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: patients treated with Dabigatran
Study NCT04974970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Immunotherapy
Description: Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
Study NCT01434290 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 36.25 Gy IMRT
Description: 36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
Study NCT01434290 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 51.6 Gy IMRT
Description: 51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
Study NCT03900299 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: oncoplastic breast surgery
Description: oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
Study NCT01823874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality distraction
Description: Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
Study NCT03688321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsule GR-1 and RC-14
Description: Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
Study NCT03688321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
Study NCT01858012 — intervention group
Intervention type: BEHAVIORAL
Intervention: Moderate alcohol cessation
Description: patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
Study NCT03658083 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracotomy
Description: Open surgery
Study NCT03658083 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic-assisted thoracic surgery
Description: Minimally invasive surgery
Study NCT01129141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-PTM
Description: Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
Study NCT00318890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
Study NCT00318890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
Study NCT01129141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wait List Control
Description: Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
Study NCT02994862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galla Chinnesis
Description: new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
Study NCT02994862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bonding
Description: Normal Bonding Protocol
Study NCT03761732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing
Description: 6 session behavioral intervention program designed to reduce PTSD and related symptomatology
Study NCT04292730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion
Study NCT02861716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study NCT03921775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: For induction and maintenance of general anesthesia
Study NCT03921775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of general anesthesia
Study NCT00545922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Seven weekly sessions (2 hrs) in groups
Study NCT00545922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Telephone Contact
Description: Telephone contact (max. 10 minutes) every other week during the 7-week intervention
Study NCT02256553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3641 12 Amb a 1-U (short ragweed extract)
Description: 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
Study NCT02256553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-7243 2800 BAU (Timothy grass extract)
Description: 2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
Study NCT02256553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication
Description: Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
Study NCT01714479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leucine-enriched nutritional supplement
Description: A protein and carbohydrate supplement with high levels of leucine
Study NCT01714479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine-enriched nutritional supplement
Description: A protein and carbohydrate supplement with high levels of leucine
Study NCT01714479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03384342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B therapy
Description: * Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month.
Study NCT04371029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSG
Description: Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
Study NCT02292056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-on-1 counseling
Description: 1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling